Search alternatives:
significant adverse » significant advantage (Expand Search), significant decrease (Expand Search)
adverse decrease » rivers decreased (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
Showing 1 - 20 results of 1,669 for search '(( significant adverse decrease ) OR ( significant gap decrease ))', query time: 0.38s Refine Results
  1. 1
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  2. 2
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  3. 3
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  4. 4
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  5. 5
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  6. 6
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  7. 7
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 8
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 9
    Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells.

    Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. by Xiang-Fan Chen (13932983)

    Published 2024
    Save to List
    Saved in:
  10. 10
    Study-related adverse events.

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    “…In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
    Save to List
    Saved in:
  11. 11
    Sobel test for the significance of the mediation effect.

    Sobel test for the significance of the mediation effect. by Getachew Magnar Kitila (19935139)

    Published 2024
    Save to List
    Saved in:
  12. 12
    Modified version of the Caregiving Stress Model for Post Intensive Care Syndrome – Family impairments.

    Modified version of the Caregiving Stress Model for Post Intensive Care Syndrome – Family impairments. by Cristobal Padilla-Fortunatti (21376807)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    SPIRIT schedule: Timeline of recruitment and assessment. <i>t</i><sub>0</sub>: Daily screening; <i>t</i><sub>1</sub>: Between the 3<sup>rd</sup> and 10<sup>th</sup> day of ICU admission; t<sub>2</sub>: Near after ICU discharge; <i>t</i><sub>3</sub>: 3 months after hospital discharge; <i>t</i><sub>4</sub>: 6 months after hospital discharge.

    SPIRIT schedule: Timeline of recruitment and assessment. <i>t</i><sub>0</sub>: Daily screening; <i>t</i><sub>1</sub>: Between the 3<sup>rd</sup> and 10<sup>th</sup> day of ICU admi... by Cristobal Padilla-Fortunatti (21376807)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Questionnaire description.

    Questionnaire description. by Cristobal Padilla-Fortunatti (21376807)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Variables and generalized linear mixed models to explore PICS-F impairments.

    Variables and generalized linear mixed models to explore PICS-F impairments. by Cristobal Padilla-Fortunatti (21376807)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments.

    Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

    Published 2025
    Save to List
    Saved in:
  17. 17
    Adverse cardiovascular events by immune checkpoint inhibitor.

    Adverse cardiovascular events by immune checkpoint inhibitor. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 18
    Presentation 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.pdf

    Presentation 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.pdf by Yi Li (1144)

    Published 2025
    Save to List
    Saved in:
  19. 19
    Distribution of cases and adverse events associated with metformin.

    Distribution of cases and adverse events associated with metformin. by Mengsi Peng (12882734)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Number of adverse reaction case reports of finasteride administration at the PT level.

    Number of adverse reaction case reports of finasteride administration at the PT level. by Xiaoling Zhong (181270)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: